xml", "id": "tbl2", "section_type": "TABLE", "type": "table_caption"}, "text": "Phase 2 studies of natalizumab", "sentences": [], "annotations": [], "relations": []}, {"offset": 9945, "infons": {"file": "tbl2.xml", "id": "tbl2", "section_type": "TABLE", "type": "table", "xml": "<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<table frame=\"hsides\" rules=\"groups\"><thead><tr><th rowspan=\"1\" colspan=\"1\"/><th align=\"left\" rowspan=\"1\" colspan=\"1\">Objectives</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Inclusion criteria</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">N</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Treatment</th><th align=\"left\" rowspan=\"1\" colspan=\"1\">Results for primary endpoint</th></tr></thead><tbody><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\"><xref ref-type=\"bibr\" rid=\"b40\">Tubridy et al 1999</xref></td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Effect of natalizumab on MRI lesions in patients with RRMS or SPMS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">18-55 years, EDSS of 2.0-7.0, >=2 relapses within past 18 months, relapse-free in past 4 weeks</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">72</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Natalizumab 3 mg/kg or placebo (1:1), at 0 and 4 weeks for a total of 2 infusions</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Mean number of new active lesions<xref ref-type=\"table-fn\" rid=\"tf2-1\">a</xref> through week 12: 1.8 natalizumab vs 3.6 placebo (p = 0.042) Mean number of new Gd+ lesions through week 12:1.6 natalizumab vs 3.3 placebo (p = 0.017)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\"><xref ref-type=\"bibr\" rid=\"b24\">Miller et al 2003</xref></td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Safety and efficacy of natalizumab in patients with RRMS or SPMS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">18-65 years, EDSS 2.0-6.5, >=2 relapses in past 2 years, >=3 T2 lesions</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">213</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Natalizumab (3 or 6 mg/kg) or placebo (1:1:1) every 4 weeks for 6 months</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Mean number of new Gd+ lesions through month 6: 0.7 natalizumab 3 mg/kg, 1.1 natalizumab 6 mg/kg, 9.6 placebo (p &lt; 0.001 for comparison of each active group vs placebo)</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\"><xref ref-type=\"bibr\" rid=\"b30\">O'Connor et al 2004</xref></td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Effect of a single dose of natalizumab in patients with RRMS or SPMS during an acute relapse</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">18-65 years, EDSS >=5.5, stable FSS scores for >=30 days prior to qualifying acute relapse<xref ref-type=\"table-fn\" rid=\"tf2-2\">b</xref></td><td align=\"left\" rowspan=\"1\" colspan=\"1\">180</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Natalizumab (1 mg/kg or 3 mg/kg) or placebo (1:1:1), single dose</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Mean change in EDSS between treatment groups at 1 week after treatment: no treatment differences were observed</td></tr><tr><td align=\"left\" rowspan=\"1\" colspan=\"1\"><xref ref-type=\"bibr\" rid=\"b16\">Goodman et al 2005</xref></td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Safety and efficacy of natalizumab when added to the standard regimen of GA in patients with RRMS</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">18-55 years, MRI lesions, EDSS 0.0-5.0, GA treatment for past 12 months, >=1 relapse in past 12 months</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">110</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Natalizumab 300 mg or placebo (1:1), every 4 weeks by IV, in addition to GA SC daily</td><td align=\"left\" rowspan=\"1\" colspan=\"1\">Rate of new active lesion development on MRI: study complete, but results not available</td></tr></tbody></table>\n"}, "text": "\tObjectives\tInclusion criteria\tN\tTreatment\tResults for primary endpoint\t \t\tEffect of natalizumab on MRI lesions in patients with RRMS or SPMS\t18-55 years, EDSS of 2.0-7.0, >=2 relapses within past 18 months, relapse-free in past 4 weeks\t72\tNatalizumab 3 mg/kg or placebo (1:1), at 0 and 4 weeks for a total of 2 infusions\tMean number of new active lesionsa through week 12: 1.8 natalizumab vs 3.6 placebo (p = 0.042) Mean number of new Gd+ lesions through week 12:1.6 natalizumab vs 3.3 placebo (p = 0.017)\t \t\tSafety and efficacy of natalizumab in patients with RRMS or SPMS\t18-65 years, EDSS 2.0-6.5, >=2 relapses in past 2 years, >=3 T2 lesions\t213\tNatalizumab (3 or 6 mg/kg) or placebo (1:1:1) every 4 weeks for 6 months\tMean number of new Gd+ lesions through month 6: 0.7 natalizumab 3 mg/kg, 1.1 natalizumab 6 mg/kg, 9.6 placebo (p < 0.